“This is a significant step in the development of M Pharma as a company," said company boss Gary Thompson.
Showing 25 of 5049
In the clinical trials, patients treated with Siliq had shown suicidal behaviour, the FDA said
HMPL-453 targets fibroblast growth factor receptors, which are central to several biological processes
M Pharmaceutical Inc. has appointed Gary Thompson as its president and chief executive officer
With the closure of that acquisition, the firm gains around seven different products, which are FDA cleared.
The grant was awarded by the Australian Federal Government.
VolitionRx Limited will present at Source Capital Group's 2nd Annual Disruptive Growth & Healthcare Conference being held on February 15-16 in New York
After a disappointing previous three months, the Dublin-based pharma beat expectations this time.
The trial involved 31 boys taking different doses of edasalonexent.
“I was pleased with the company’s overall performance during 2016," said chief executive Ian Read.
M Pharmaceutical Inc said it has repriced, from 50 cents to five cents per share, 4,375,000 options expiring on Feb. 6, and 1,025,000 options expiring on Feb. 13
Pressure Biosciences Inc said on Tuesday Richard T. Schumacher, President and CEO, is scheduled to present at RedChip's Global Online Growth Conference on Wednesday January 25, 2017, at 11:30am EST
Through the acquisition of 40 J's, M will acquire patented technologies to deliver phytoestrogens for the treatment of the symptoms of menopause
It made the decision about the Opdivo and Yervoy combination after assessing the data available
Prior to joining Motif Bio, Dickey was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company
“Summit has two strong scientific programmes with the potential to significantly advance the current standard of care in their respective disease areas," said new COO Dr David Roblin.
Sales reached a new high of $2.2 million in the period, it said, as it revealed an overall 2016 revenue of $8.2 million - a 28% increase on the previous year.
The drug product would be targeted at women with orgasm and arousal difficulties
Living Cell Technologies’ (ASX:LCT) patent application related to choroid plexus cells has been published by the U.S. patent office.
US officials said Shire Pharmaceuticals will pay $350m to settle allegations that it used “kickbacks and other unlawful methods” to induce doctors to use a product aimed at treating foot ulcers
Pressure Biosciences' President and CEO Richard T. Schumacher will present a corporate overview at the 9th Annual Biotech Showcase at 1700 PST later today
The Canadian group announced the deal to acquire Cincinatti-based 40Js on 4 January
Clinigen and Cumberland formed their alliance last year and have already launched one drug, Ethyol
M Pharma has signed a letter of intent to buy 100% of Cincinnati-based healthcare group 40J’s LLC
VolitionRx announced on Wednesday that it will present at the 9th annual Biotech Showcase Conference being held from January 9-11 in San Francisco, CA